Table 1.
Preoperative clinical characteristics of patients with pancreatic cystic neoplasms
| Characteristics |
Training cohort
|
Validation cohort
|
P
value
|
|
n
= 187 (64.5%)
|
n
= 103 (35.5%)
|
||
| Sex | 0.190 | ||
| Male | 126 (67.4) | 77 (74.8) | |
| Female | 61 (32.6) | 26 (25.2) | |
| Age in yr | 0.344 | ||
| < 60 | 123 (65.8) | 62 (60.2) | |
| ≥ 60 | 64 (34.2) | 41 (39.8) | |
| BMI | 23.25 ± 3.37 | 23.00 ± 3.53 | 0.561 |
| Weight loss | 0.830 | ||
| No | 165 (88.2) | 90 (87.4) | |
| Yes | 22 (11.8) | 13 (12.6) | |
| Alcohol | 0.378 | ||
| No | 168 (89.8) | 89 (86.4) | |
| Yes | 19 (10.2) | 14 (13.6) | |
| Symptomatic | 0.602 | ||
| No | 74 (39.6) | 44 (42.7) | |
| Yes | 113 (60.4) | 59 (57.3) | |
| NLR | 0.510 | ||
| < 2.288 | 134 (71.7) | 70 (68.0) | |
| ≥ 2.288 | 53 (28.3) | 33 (32.0) | |
| TB in μmol/L | 0.763 | ||
| < 34.2 | 181 (96.8) | 99 (96.1) | |
| ≥ 34.2 | 6 (3.2) | 4 (3.9) | |
| CEA in ng/mL | 0.901 | ||
| < 5 | 175 (93.6%) | 96 (96.0%) | |
| ≥ 5 | 12 (6.4) | 7 (7.0) | |
| CA19-9 in U/mL | 0.135 | ||
| < 34 | 163 (87.2) | 83 (80.6) | |
| ≥ 34 | 24 (12.8) | 20 (19.4) | |
| GGT in IU/L | 0.287 | ||
| < 150 | 174 (93.0) | 99 (96.1) | |
| ≥ 150 | 13 (7.0) | 4 (3.9) | |
| ALP in IU/L | 0.556 | ||
| < 200 | 179 (95.7) | 97 (94.2) | |
| ≥ 200 | 8 (4.3) | 6 (5.8) |
ALP: Alkaline phosphatase; BMI: Body mass index; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; GGT: γ-glutamyl transpeptidase; NLR: Neutrophil-to-lymphocyte; TB: Total bilirubin.